Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2325-2330

  Mulloy, Roseann ^a   Ferrand, Audrey ^a   Kim, Youngjoo ^b   Sordella, Raffaella ^a   Bell, Daphne W ^a   Haber, Daniel A ^a   Anderson, Karen S ^b   Settleman, Jeffrey ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MUTANT PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CATALYSIS; DRUG INHIBITION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BACULOVIRIDAE; CATALYSIS; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTANT PROTEINS; PHOSPHOTRANSFERASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPODOPTERA; SUBSTRATE SPECIFICITY;

EID: 33947287270     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4293     Document Type: Article

References (20)

1. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19: 6550-65.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
5. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
6. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
7. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
8. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-6.
9. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
10. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005; 65:7096-101.
11. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005;65:8968-74.
12. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
13. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
14. Furdui CM, Lew ED, Schlessinger J, Anderson KS. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 2006; 21:711-7.
15. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
16. Jan AY, Johnson EF, Diamonti AJ, Carraway IK, Anderson KS. Insights into the HER-2 receptor tyrosine kinase mechanism and substrate specificity using a transient kinetic analysis. Biochemistry 2000;39:9786-803.
17. Johnson SA, Hunter T. Phosphoproteomics finds its timing. Nat Biotechnol 2004;22:1093-4.
18. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
19. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem J 2006;397:537-43.
20. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71.